

A Richard Green

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3868216/a-richard-green-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

2,195
citations

18
h-index

32
g-index

32
ext. papers

2,343
ext. citations

5.8
avg, IF

4.65
L-index

#	Paper	IF	Citations
31	The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). <i>Pharmacological Reviews</i> , 2003 , 55, 463-508	22.5	944
30	A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. <i>European Journal of Pharmacology</i> , 2004 , 500, 3-13	5.3	138
29	Animal models of stroke: do they have value for discovering neuroprotective agents?. <i>Trends in Pharmacological Sciences</i> , 2003 , 24, 402-8	13.2	138
28	3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. <i>Psychopharmacology</i> , 2001 , 154, 251-60	4.7	122
27	Therapeutic strategies for the treatment of stroke. <i>Drug Discovery Today</i> , 2006 , 11, 681-93	8.8	120
26	A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. <i>British Journal of Pharmacology</i> , 2001 , 134, 1711-23	8.6	95
25	Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059 2003 , 100, 195-214		88
24	Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1085-95	1.2	65
23	Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. <i>British Journal of Pharmacology</i> , 2005 , 146, 306-12	8.6	59
22	Neuropharmacology of 5-hydroxytryptamine. <i>British Journal of Pharmacology</i> , 2006 , 147 Suppl 1, S145-58.6		58
21	Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. <i>Journal of Psychopharmacology</i> , 2004 , 18, 412-6	4.6	56
20	MDMA: on the translation from rodent to human dosing. <i>Psychopharmacology</i> , 2009 , 204, 375-8	4.7	46
19	Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. <i>Psychopharmacology</i> , 2004 , 173, 264-9	4.7	41
18	Optimising in vivo pharmacology studies--Practical PKPD considerations. <i>Journal of Pharmacological and Toxicological Methods</i> , 2010 , 61, 146-56	1.7	40
17	Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. <i>Psychopharmacology</i> , 2011 , 213, 365-76	4.7	32
16	Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine. <i>Neuropharmacology</i> , 2014 , 87, 125-34	5.5	28
15	Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone. <i>Addiction Biology</i> , 2016 , 21, 1127-1139	4.6	26

14	The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy"). <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 84, 261-6		21
13	MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press. <i>Psychopharmacology</i> , 2004 , 173, 231-3	4.7	15
12	Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2114-2122	3.8	14
11	Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). <i>Journal of Psychopharmacology</i> , 2014 , 28, 711-8	4.6	13
10	Caffeine alters the behavioural and body temperature responses to mephedrone without causing long-term neurotoxicity in rats. <i>Journal of Psychopharmacology</i> , 2016 , 30, 698-706	4.6	10
9	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1668-1685	3.8	6
8	From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 959-67	3.8	4
7	How do we re-engage the pharmaceutical industry in research on serotonin and psychiatric disorders?. <i>ACS Chemical Neuroscience</i> , 2013 , 4, 9-12	5.7	4
6	Induction of the cell survival kinase Sgk1: A possible novel mechanism for β -phenyl-N-tert-butyl nitronone in experimental stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 1111-1121	7.3	4
5	Examining the 'psychopharmacology revolution' (1950-1980) through the advertising of psychoactive drugs in the British Medical Journal. <i>Journal of Psychopharmacology</i> , 2018 , 32, 1056-1066	4.6	4
4	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1901-1906	3.8	3
3	MDMA and Other Club Drugs 2007 ,		1
2	Starting with serotonin. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 903-904	3.8	0
1	A Brief History of Psychopharmacology 2020 , 1-34		